Radio-labelling of proteins
AssigneeBritish Technology Group Limited
InventorsBrian Maurice John Foxwell, Peter Parker, Andrew Malcolm Creighton
Life of this patent
Estimating the term…
Abstract
Nucleoside thiotriphosphates carrying .sup.32 P in the gamma-thiophosphate group, prepared by reaction between a nucleoside diphosphate and .sup.32 p labelled thiophosphate salt, are used as thiophosphorylating agents for antibodies that bind to tumour-associated antigens. The labelled thiotriphosphates can be used to introduce a therapeutically useful .sup.32 P atom into an antibody that has been modified by the incorporation into its structute of a peptide region capable of acting as a substrate for a phosphokinase. The resulting labelled antibody can then be used for injection in anti-tumour therapy and has clinical advantages over the corresponding phosphoylated analogue.
Claims10
A .sup.32 P thiophosphorylated antibody or antigen binding fragment thereof that will bind with a tumor-associated structure wherein said antibody or antigen binding fragment thereof has been thiophosphorylated with compound of the formula ##STR4## in which A represents a nucleoside residue and the phosphorus in the gamma-thiophosphate group is .sup.32 P.
A process for the production of a .sup.32 P thiophosphorylated antibody or antigen binding fragment thereof, which process comprises reacting a compound of formula ##STR5## in which A represents a nucleoside residue and the phosphorus in the gamma-thiophosphate group is .sup.32 P, in the presence of a phosphokinase with an antibody or antigen binding fragment thereof which includes a peptide region capable of acting as a substrate for the phosphokinase.
Dependencies are inferred from the claim text.